nsps are believed to form a membrane-bound multienzyme complex, which is called the replicase-transcriptase complex (47, 52) .
The proteins located downstream (i.e., carboxy terminal) of nsp5 in pp1a/pp1ab include key replicative enzymes of the virus, such as RNA-dependent RNA polymerase (nsp12) (12) , RNA helicase (nsp13) (50) , exoribonuclease (nsp14) (42) , endoribonuclease (nsp15) (6, 31) , and putative methyltransferase (nsp16) activities (53, 64) . They also include several small proteins, nsp7 to nsp10, which typically have RNA-binding activities (18, 32, 40, 56, 63) and therefore are believed to be involved in viral RNA synthesis, as well as the hydrophobic, probably membrane-spanning protein nsp6. Because of its key role in the proteolytic release of all these proteins, the nsp5-associated cysteine protease activity is critically involved in viral replication and therefore is often referred to as the CoV "main protease" (M pro ) (64, 66) . The nsp5-associated M pro has a chymotrypsin-like fold that is fused to a unique carboxyterminal domain and displays a narrow substrate specificity that resembles that of picornavirus 3C proteases (2, 3, 21, 66) . The M pro -mediated processing pathways are well conserved: in all CoVs, M pro cleaves as many as 11 pp1a/pp1ab sites to produce a total of 13 mature proteins. Consequently, the patterns of M pro -mediated processing are likely to be very similar for all CoVs (64) .
Proteins upstream of nsp5 include (i) the hydrophobic, membrane-bound nsp4; (ii) two large multidomain proteins (nsp2 and nsp3); and (iii) the amino-terminal product, nsp1, which is found in most, but not all, CoVs (Fig. 1) . The aminoproximal pp1a/pp1ab proteins nsp1 to nsp3 are relatively poorly conserved (53, 67) , and there is evidence that some of these proteins, or their subdomains, are not essential (11, 25, 43) . Hence, the nsp3-associated cysteine proteases PL1 pro and PL2 pro , which control the proteolytic processing of this pp1a/ pp1ab region, are also referred to as CoV "accessory proteases" (64, 66) . nsp4 is sandwiched between the autoproteolytically released proteins nsp3 and nsp5, and accordingly, its release from pp1a/pp1ab is under the control of both main and accessory proteases.
The multidomain protein nsp3 is the largest CoV replicative protein (67) . It has a size of ϳ1,700 to 1,900 amino acids and includes one or two proteases, called PL1 pro and PL2 pro , that adopt a papain-like fold, with amino-and carboxy-terminal domains connected by a Zn ribbon structure (22, 29, 44) . PL1 pro and PL2 pro reside upstream and downstream, respectively, of the conserved ADP-ribose-1Љ-phosphatase (ADRP) domain (19, 22, 43, 46, 53) whose biological function is not yet known (Fig. 1) . Several other domains were provisionally identified in nsp3, with two of them, an acidic (Ac) domain at the amino terminus and a Cys/His-rich domain at the carboxy terminus (the Y domain), being conserved in all CoVs (67) . Also, PL2 pro is conserved in all CoVs. The protease is aminoterminally extended by a small ubiquitin-like (Ubi) domain that probably modulates the PL2 pro deubiquitinating activity (5, 44, 54) . In contrast, PL1
pro was identified only in CoVs belonging to genetic group 1 and subgroup 2a. Subgroup 2b CoVs, including severe acute respiratory syndrome (SARS)-CoV, do not encode a PL1
pro (39, 45, 53, 60) , whereas group 3 CoVs (prototype, infectious bronchitis virus [IBV] ) possess a PL1 pro remnant that lacks proteolytic activity (67) . Besides differences in the domain organization of nsp1 to nsp3, there are also differences in the proteolytic-processing pathways among the various groups and subgroups of CoVs. Thus, for example, in the CoV groups 2b and 3, which specify a single papain-like protease activity, the PL2 pro activity is responsible for the processing of the entire amino-proximal region to produce two or three mature proteins (27, 36, 37, 60) . These PL2 pro cleavage sites have three strictly conserved residues at their P4 to P1 positions (60) . By contrast, in CoVs encoding two PL pro s, the regulation of the proteolytic-processing pathways seems to be more complex. For example, in mouse hepatitis virus (MHV), the prototype of CoV group 2a, PL1 pro cleaves the nsp1-nsp2 and nsp2-nsp3 sites, while PL2 pro cleaves the nsp3-nsp4 site (4, 7, 8, 15, 24, 34, 57) . Accordingly, the MHV PL1 pro and PL2 pro cleavage sites resemble each other only remotely in that both of them have small amino acid residues at their P2 and/or P1 positions. In human CoV 229E (HCoV-229E), a group 1 CoV, the situation is again different. Here, the nsp1-nsp2 site was reported to be processed by PL1 pro , whereas the nsp2-nsp3 site can be processed by either PL1 pro or PL2 pro , with PL2 pro being the dominant activity (28, 67) . Accordingly, these sites, and the yet-to-be-verified HCoV-229E nsp3-nsp4 site, are more similar to each other, resembling the situation found in CoVs encoding just one active PL pro (60) .
In this study, we have characterized the proteolytic regula-
CoV PL pro -mediated polyprotein processing. The pp1a/pp1ab amino-terminal regions of HCoV-229E (group 1), MHV (group 2a), SARS-CoV (SCoV, group 2b), and IBV (group 3) are shown with the previously identified processing end products nsp1 to nsp4 and the corresponding cleavage sites (P1 and PЈ residues are indicated). The sites processed by specific protease domains are indicated by arrows. P1 and PЈ residues are given. Ac, acidic domain; PL1, papain-like protease 1; X, ADP-ribose-1Љphosphatase; PL2, papain-like protease 2; Y, domain with conserved Cys/His residues and putative transmembrane regions; SUD, SARS-CoV specific domain.
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CORONAVIRUS PAPAIN-LIKE PROTEINASE FUNCTION 3923 tion of HCoV-229E nsp1 synthesis using reverse genetics. The HCoV-229E nsp1 belongs to an uncharacterized protein family that is conserved in group 1 CoVs. It is distinct from the nsp1 protein family of group 2 CoVs, which was recently shown for MHV to affect diverse host cell functions (33) . In our study, we sought to answer the question of whether, and to what extent, the two PL pro activities were involved in the proteolytic release of nsp1. We used the HCoV-229E reverse-genetics system (58) to produce mutants in which one of the protease activities, either PL1 pro or PL2 pro , was abolished by codon mutagenesis of the active-site nucleophile. The data show that inactivation of PL2 pro is lethal, whereas the PL1 pro activity is dispensable for HCoV-229E replication, as demonstrated by Northern blot analysis of viral RNA synthesis and the rescue of a viable PL1 pro -negative mutant. However, upon passage in cell culture, the PL1 pro -negative mutant reverted to the wild-type sequence, indicating selective pressure to restore the PL1 pro activity. Our further analysis revealed that PL2
pro is able to cleave the nsp1-nsp2 site, although less efficiently than does PL1 pro . Finally, by uncoupling cleavage of the nsp1-nsp2 site from the two PL pro activities, we managed to stably maintain the PL1
pro -negative mutant genotype in cell culture. This suggests that the major driving force for the reversion of the PL1 pro mutation was the requirement for an efficient cleavage of the nsp1-nsp2 site. Taken together, our data provide further evidence for overlapping substrate specificities of the PL1 pro and PL2
pro domains in HCoV-229E. In this functional cooperation, the essential PL2 pro domain plays a major and clearly dominant proteolytic role, whereas the dispensable paralogous PL1 pro may have evolved to at least partially liberate the PL2 pro domain from its role in efficient nsp1-nsp2 processing.
MATERIALS AND METHODS
Viruses and cells. MRC-5 and CV-1 cells were purchased from the European Collection of Cell Cultures. D980R cells were a kind gift from G. L. Smith, Imperial College, London, United Kingdom. BHK-HCoV-N cells, expressing the HCoV-229E nucleocapsid protein under the control of the TET/ON system (Clontech), have been described previously (49, 62) . All cells were maintained in minimal essential medium supplemented with fetal bovine serum (5 to 10%) and antibiotics. HCoVs and recombinant vaccinia viruses were propagated, titrated, and purified as described previously (58) .
Cloning of plasmid DNAs and recombinant vaccinia viruses. To generate recombinant vaccinia viruses, the following plasmid DNAs were constructed using standard procedures. The details of construction and plasmid maps and sequences are available from the authors upon request.
To construct the recombinant vaccinia virus vHCoV-PL1 pro (Ϫ), two DNA fragments, designated EB-PL1 pro (Ϫ) and BF, were produced. These fragments together include HCoV-229E nucleotides (nt) 1 to 7006. The first fragment, EB-PL1 pro (Ϫ), includes HCoV-229E nt 1 to 5207, contains the PL1 pro active-site Cys1054Ala mutation, and was constructed as follows. Plasmid DNA pEB (carrying HCoV-229E nucleotides 1 to 5207 preceded by one additional G nucleotide and the T7 RNA polymerase promoter) (59) was modified to introduce the PL1 pro active-site Cys1054Ala mutation. Briefly, two PCRs were done using the vHCoV-inf-1 DNA (58) pro (Ϫ), the ligation reaction was transfected without further purification into fowlpox-infected CV-1 cells as described previously (58) . To identify a correct vHCoV-PL1 pro (Ϫ) clone, the recombinant vaccinia virus clones obtained were analyzed by Southern blotting, PCR, and sequence analysis of HCoV-229E nt 1 to 7100.
The recombinant vaccinia virus vHCoV-PL2 pro (Ϫ) was constructed similarly to the recombinant vaccinia virus vHCoV-PL1 pro (Ϫ) by in vitro ligation. First, plasmid DNA pEB (see above) was cleaved with EagI and BglII and treated with alkaline phosphatase, and the resulting DNA fragment, EB (HCoV-229E nt 1 to 5207), was gel purified. The DNA fragment PCR-BF encompassing HCoV-229E nt 5176 to 7006 (59) was modified to introduce the PL2 pro active-site Cys1701Ala mutation as follows. PCR1-PL2 pro (Ϫ) was done with primers Bgl-up and JZ214 (5Ј-TATAGGTCTCAATGCATTATTATCACTAGTTTTTAACAC-3Ј (the BsaI restriction site is in italics, and the antisense Ala1701 codon is underlined). PCR2-PL2 pro (Ϫ) was done using primer JZ215 (5Ј-TATAGGTCTCAG CATGGGTGAATGCTGTTTGTATTGCAC 5420-3Ј (the BsaI restriction site is in italics, and the Ala1701 codon is underlined) and primer Fse-down. Both PCR products were cleaved with BsaI and ligated. The resulting ligation product, BF-PL2 pro (Ϫ), was cleaved with BglII and ligated to DNA fragment EB. The resulting ligation product [EB-BF-PL2 pro (Ϫ)] was cleaved with FseI, purified, and used in an in vitro ligation reaction with NotI-cleaved vaccinia virus vNotI/tk genomic DNA and FseI-cleaved vaccinia virus vHCoV-inf-1 DNA. To rescue recombinant vaccinia virus vHCoV-PL2 pro (Ϫ), the ligation reaction was transfected without further purification into fowlpox-infected CV-1 cells. To identify a correct vHCoV-PL2 pro (Ϫ) clone, the recombinant vaccinia virus clones obtained were analyzed by Southern blotting, PCR, and sequence analysis of HCoV-229E nt 1 to 7100.
To construct the recombinant vaccinia viruses vPL1(ϩ)/PL2(ϩ), vPL1(Ϫ)/ PL2(ϩ), and vPL1(ϩ)/PL2(Ϫ), we first generated two plasmid DNAs, designated p7E1N and pFse3C. Plasmid DNA p7E1N was based on pBluescipt-KS(ϩ) (Stratagene) and contained the bacteriophage T7 RNA polymerase promoter, the encephalomyocarditis virus internal ribosomal entry site (EMCV-IRES), and HCoV-229E nt 293 to 1485. Plasmid DNA pFse-3C contained HCoV-229E nt 6993 to 9187, a TAA stop codon, the HCoV-229E 3Ј end (nt 27221 to 27277), a synthetic poly(A) sequence of 37 nt, and an EagI restriction site. The vaccinia virus inserts were assembled by in vitro ligation using three DNA fragments. Fragment 1 contained the T7 RNA polymerase promoter, the EMCV-IRES element, and HCoV-229E nt 293 to 1260 and was prepared from plasmid DNA p7E1N by EagI and SapI cleavage, alkaline phosphatase treatment, and gel purification. Three versions of fragment 2, encompassing HCoV-229E nt 1261 to 6995, were prepared by PCR using vaccinia virus genomic DNAs from vHCoVinf-1, vHCoV-PL1 pro (Ϫ), and vHCoV-PL2 pro (Ϫ), respectively, as templates and subsequently cleaved with SapI and FseI. Depending on the DNA template used for PCR, the different versions of fragment 2 encoded either (i) two active PL pro s, (ii) an inactive PL1 pro and an active PL2 pro , or (iii) an active PL1 pro and an inactive PL2 pro . Fragment 3 was prepared from plasmid DNA pFse3C by FseI and EagI cleavage, alkaline phosphatase treatment, and gel purification and encompassed HCoV-229E nt 6996 to 9187, a TAA stop codon, HCoV-229E nt 27221 to 27277, and a synthetic poly(A) sequence of 37 nt. After in vitro ligation of fragments 1, 2, and 3, the ligation products were ligated to NotI-cleaved vaccinia virus vNotI/tk genomic DNA. Rescue of recombinant vaccinia viruses vPL1(ϩ)/PL2(ϩ), vPL1(Ϫ)/PL2(ϩ), and vPL1(ϩ)/PL2(Ϫ) was done by transfection of the ligation products into fowlpox-infected CV-1 cells. The identities of recombinant vaccinia virus clones were confirmed by Southern blotting and sequence analysis.
Construction of recombinant vaccinia virus vHCoV-TaV-PL1 pro (Ϫ) was done by vaccinia virus-mediated homologous recombination using the Escherichia coli guanine phosphoribosyltransferase (gpt) gene as a marker for positive and negative selection, as described previously (30) . We used plasmid DNA pRec-2 (30) for recombination with vHCoV-PL1 pro (Ϫ), resulting in the gpt-positive clone vHCoV-PL1 pro (Ϫ)-Rec-2. The second recombination was done with vHCoV-PL1 pro (Ϫ)-Rec-2 and plasmid DNA pEx2-TaV, which contains a 500-nt HindIII-NotI fragment derived from vaccinia virus vNotI/tk, the T7 RNA polymerase promoter, one G nucleotide, HCoV-229E nt 1 to 616, the sequence encoding the Thosea asigna virus 2A-like autoprocessing peptide (16) , and HCoV-229E nt 626 to 3323. The identity of the resulting recombinant vaccinia virus clone, vHCoV- TaV-PL1 pro (Ϫ), was verified by Southern blotting and sequence analysis of the region where recombination had occurred.
Rescue of recombinant HCoV-229E and HCoV-229E mutants. In vitro transcription from recombinant vaccinia virus genomic DNA using bacteriophage T7 RNA polymerase in the presence of an m7G(5Ј)ppp(5Ј)G cap analog was done as described previously (58, 59) . To rescue recombinant HCoV-229E, BHKHCoV-N cells were electroporated with full-length recombinant HCoV-229E RNA. On day 3, tissue culture supernatant was transferred to MRC-5 cells (passage 1).
RNA preparation, Northern blotting, RT-PCR, and sequence analysis. Poly(A)-containing RNA was isolated from BHK-HCoV-N cells that had been electroporated with recombinant HCoV-229E RNA or from infected MRC-5 cells using oligo(dT) 25 Dynabeads (Dynal, Oslo, Norway) as described previously (61) . Northern blot analysis was done with a 32 P-labeled probe specific for the HCoV-229E nt 26297 to 27273, as described previously (60) . Reverse transcription (RT)-PCR was done with Superscript II reverse transcriptase (Invitrogen). Sequence analysis of plasmid DNA, RT-PCR products, and recombinant vaccinia virus cDNA inserts was done by standard cycle-sequencing methods with an ABI 310 Prism Genetic Analyzer. Computer-assisted analysis of sequence data was facilitated by the Lasergene biocomputing software (DNASTAR).
Metabolic labeling, cell lysis, and immunoprecipitation. Vero cells (2 ϫ 10 6 ) were coinfected with modified vaccinia virus Ankara (MVA) expressing T7 RNA polymerase (55) (multiplicity of infection [MOI] ϭ 5) and one of the recombinant vaccinia viruses vNotI/tk, vPL1(ϩ)/PL2(ϩ), vPL1(Ϫ)/PL2(ϩ), and vPL1(ϩ)/PL2(Ϫ), respectively (MOI ϭ 15). At 4.5 h postinfection (p.i.), the cells were labeled metabolically for 6 h using 100 Ci/ml of L-[
35 S] in vitro celllabeling mix (GE Healthcare) as described previously (65) . At 10.5 h p.i., the radiolabeled cells were washed twice in ice-cold phosphate-buffered saline and lysed in 1 ml RIPA buffer (10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% sodium deoxycholate, 1% Triton X-100, 0.1% sodium dodecyl sulfate [SDS]) containing protease inhibitors. After 30 min at 4°C, the lysates were centrifuged (10 min; 14,000 ϫ g; 4°C) and the soluble protein fraction was mixed with 50 ml Pansorbin (Calbiochem) and incubated overnight at 4°C. The Staphylococcus aureus cells were pelleted, and the preabsorbed cell lysate was divided into two aliquots. Ten microliters of either an nsp1-specific antiserum, ␣-nsp1, or the corresponding preimmune serum was added to these aliquots, and the reaction mixtures were incubated for 2 h at 4°C. Next, 40 l protein A-Sepharose bead suspension was added, and the reaction mixtures were incubated for 60 min at 4°C. Thereafter, the beads were pelleted, washed three times with 900 l RIPA buffer, and resuspended in 40 l Laemmli sample buffer, and the samples were heated for 5 min at 96°C. After a brief centrifugation step, the supernatant fractions were separated in SDS-17% polyacrylamide gels, and the precipitated proteins were visualized by autoradiography of the dried gels. The nsp1-specific serum used in these experiments was obtained by immunizing New Zealand White rabbits with a histidine-tagged form of nsp1 (HCoV-229E pp1a/pp1ab residues 1 to 111), which was expressed in Escherichia coli and purified under denaturing conditions.
RESULTS

PL1
pro , but not PL2 pro , activity is dispensable for HCoV-229E replication. We first determined if both PL pro activities were required for HCoV-229E replication. To do this, two mutant HCoV-229E full-length cDNAs, in which one of the active-site cysteine codons was replaced by an alanine codon, were constructed ( Fig. 2A) . One mutant cDNA, vHCoV-PL1 pro (Ϫ), was designed to inactive the PL1 pro activity (Cys1054Ala), and the other, vHCoV-PL2 pro (Ϫ), was designed to inactivate the PL2 pro activity (Cys1701Ala). Both cDNA constructs were generated using our HCoV-229E full-length cDNA cloned in vaccinia virus (vHCoV-inf-1) as described in Materials and Methods. Full-length (wild-type and mutant) HCoV-229E RNAs were transcribed in vitro using genomic DNAs prepared from the recombinant vaccinia viruses vHCoV-inf-1, vHCoV-PL1 showed that all species of viral RNAs were produced (Fig. 2C, lanes 3 and 4) . By contrast, in three independent experiments, we could neither detect HCoV-PL2 pro (Ϫ)-specific viral RNAs by Northern blot analysis nor rescue viable HCoV-PL2 pro (Ϫ) virus, indicating that inactivation of the PL2 pro activity is lethal. Recombinant HCoV-PL1 pro (؊) grows to reduced titers and reverts to the wild-type sequence. To verify that we had indeed rescued the original mutant, HCoV-PL1 pro (Ϫ), the relevant genome region was amplified by RT-PCR and sequenced. The data provided conclusive evidence for the presence of the introduced nucleotide changes UGC (Cys) to GCC (Ala) in viral RNA isolated from HCoV-PL1 pro (Ϫ) RNA-transfected BHK-HCoV-N cells (passage 0) and in viral RNAs isolated from infected MRC-5 cells at passages 1 and 2. However, at passage 3, a reversion of the GCC codon to the wild-type UGC codon became apparent, indicating that the introduced nucleotide changes were not stably maintained in tissue culture (Fig.  3A) . Interestingly, the reversion pattern shown in Fig. 3A was highly reproducible, as the mixed sequence was detectable exactly at passage 3 in two separate experiments.
Although the reversion of HCoV-PL1 pro (Ϫ) to the wild-type sequence precluded the generation of a high-titer stock for detailed phenotypic analysis, we were able to collect passage 1-derived tissue culture supernatants from five individual rescue experiments, which allowed us to assess the growth kinetics of HCoV-PL1 pro (Ϫ). MRC-5 cells were infected with HCoV-229E or HCoV-PL1 pro (Ϫ) (MOI ϭ 1), and viral RNAs and virus production were analyzed by Northern blotting and titration, respectively. Compared to HCoV-229E, HCoV-PL1 pro (Ϫ) displayed reduced growth kinetics and peak titers (Fig. 3B) . Furthermore, the amounts of viral RNAs accumulating over time in HCoV-PL1 pro (Ϫ)-infected MRC-5 cells were reduced (Fig. 3C) , indicating that the reduced viral titers most likely resulted from the reduced amounts or stability of viral RNAs.
Assessment of PL pro -mediated nsp1-nsp2 cleavage. The reproducible reversion of HCoV-PL1 pro (Ϫ) to the wild-type sequence after three or four passages in tissue culture indicated to us that there was strong selection pressure for a proteolytically active PL1 pro enzyme. HCoV-229E PL1 pro can cleave pp1a/pp1ab at the nsp1-nsp2 and nsp2-nsp3 cleavage sites in vitro. Since PL2 pro dominates over PL1 pro at the latter site (67), we reasoned that an active PL1 pro enzyme might be primarily important for ensuring an efficient cleavage of the nsp1-nsp2 site. Indeed, nsp1-nsp2 cleavage site mutants of the group 1 CoVs transmissible gastroenteritis virus (20) and HCoV-229E (unpublished data), as well as the group 2a CoV MHV (14) , were all revealed to display reduced growth kinetics similar to that of the HCoV-PL1 pro (Ϫ) mutant. Therefore, it seemed reasonable to assess the cleavage efficiency of the nsp1-nsp2 site in the absence of an active PL1 pro enzyme. Unfortunately, the relatively rapid reversion and the reduced growth kinetics of HCoV-PL1 pro (Ϫ) posed a significant obstacle to the analysis of the nsp1-nsp2 cleavage in HCoV-PL1 pro (Ϫ)-infected cells. To study the effects of PL1 pro inactivation on the processing of the nsp1-nsp2 site, we therefore resorted to an alternative strategy. We cloned, in vaccina virus, the entire nsp1-to-nsp4 coding region (which includes all three PL pro cleavage sites) downstream of a bacteriophage T7 RNA polymerase promoter and an EMCV-IRES element (Fig. 4A) . To provide nsp4 with its authentic carboxy terminus, a translational stop codon was introduced directly downstream of the carboxy-terminal glutamine residue of nsp4. By in vitro liga-
FIG. 4. Analysis of PL
pro -mediated nsp1-nsp2 cleavage. (A) Heterologous sequences engineered into the recombinant vaccinia viruses vPL1(ϩ)/PL2(ϩ), vPL1(Ϫ)/PL2(ϩ), and vPL1(ϩ)/PL2(Ϫ). The bacteriophage T7 RNA polymerase promoter (T7 prom.), the EMCV-IRES element, the HCoV-229E nsp1-to-nsp4 region, and the introduced active-site amino acid changes within the PL1 pro and PL2 pro domains are indicated. The vertical arrows depict PL pro cleavage sites. (B) Vero cells (2 ϫ 10 6 ) were coinfected with MVA expressing T7 RNA polymerase (MVA-T7) and vaccinia viruses vNotI/tk, vPL1(ϩ)/PL2(ϩ), vPL1(Ϫ)/PL2(ϩ), and vPL1(ϩ)/PL2(Ϫ), respectively. Infected cells were metabolically labeled from 4.5 to 10.5 h p.i., and pp1a/pp1ab processing products were immunoprecipitated using the nsp1-specific rabbit antiserum ␣-nsp1. The precipitated proteins were separated by SDS-polyacrylamide gel electrophoresis and visualized by autoradiography. The masses of marker proteins are indicated on the left. Lanes 1, 5, and 9, coinfection of MVA-T7 and vNotI/tk (vv); lanes 2, 6, and 10, coinfection of MVA-T7 and vPL1(ϩ)/PL2(ϩ); lanes 3, 7, and 11, coinfection of MVA-T7 and vPL1(Ϫ)/PL2(ϩ); lanes 4, 8, and 12, coinfection of MVA-T7 and vPL1(ϩ)/ PL2(Ϫ). The radiolabeled proteins were analyzed either directly (lanes 1, 2, 3, and 4) or after immunoprecipitation with ␣-nsp1 serum (lanes 9, 10, 11, and 12) or the corresponding preimmune serum (lanes 5, 6, 7, and 8). Three microliters of each of the total lysates was loaded in lanes 1 to 4, whereas 500 l of total cell lysate was used for the immunoprecipitation reactions analyzed in lanes 5 to 12. Ac, acidic domain; PL1, papain-like protease 1; X, ADP-ribose-1Љ-phosphatase; PL2, papain-like protease 2; Y, domain with conserved Cys/His residues and putative transmembrane regions. pro and an inactive PL2 pro (Cys1701Ala). As shown in Fig.  4B , infection of Vero cells with these recombinant vaccinia viruses in combination with MVA expressing the bacteriophage T7 RNA polymerase enabled us to detect nsp1 expression by immunoprecipitation using an nsp1-specific rabbit antiserum. Consistent with the previously established role of PL1 pro in nsp1-nsp2 processing (28), fully processed nsp1 was readily detectable in vPL1(ϩ)/PL2(ϩ)-and vPL1(ϩ)/PL2(Ϫ)-infected cells, indicating efficient processing of the nsp1-nsp2 cleavage site under these conditions (as observed in HCoV-229E-infected cells). Notably, fully processed nsp1 was also detectable in vPL1(Ϫ)/PL2(ϩ)-infected cells, indicating that HCoV-229E PL2 pro can also mediate cleavage of the nsp1-nsp2 cleavage site. However, in this case, and in clear contrast to the other two constructs tested, the fraction of released nsp1 was strongly reduced and a protein corresponding to the size of unprocessed nsp1-nsp2 was precipitated. This led us to conclude that the PL2 pro activity can cleave both the nsp1-nsp2 and nsp2-nsp3 sites, although PL2
pro -mediated processing is less efficient than PL1 pro -mediated processing at the nsp1-nsp2 site.
Uncoupling of nsp1-nsp2 processing from viral PL pro activities allows the recovery of PL1 pro -deficient HCoV-229E that can be stably propagated in cell culture. The results presented above were consistent with our hypothesis that the requirement for efficient processing of the nsp1-nsp2 site is a major driving force for the conservation of a proteolytically active PL1 pro in HCoV-229E. To further support this hypothesis, we decided to characterize a mutant in which the cleavage of the nsp1-nsp2 site was uncoupled from the activities of HCoV-229E-encoded PL pro s. To this end, we replaced in the vHCoV-PL1 pro (Ϫ) cDNA the codons specifying the three consecutive glycine residues at the P3-to-P1 positions of the nsp1-nsp2 cleavage site with the coding sequence of a "2A-like" autoprocessing peptide derived from Thosea asigna virus (TaV-2A) (16) (see Materials and Methods). As a result of this replacement, PL pro -mediated cleavage of the nsp1-nsp2 site was abolished, but the efficient release of nsp1 from pp1a/pp1ab was maintained by the activity of the TaV-2A element engineered at the interprotein junction. This element is proposed to mediate a translational termination and reinitiation at the carboxy-terminal glycine/proline residues of the TaV-2A peptide (Fig. 5A) (17) , resulting in an nsp1 that is extended at its carboxy terminus by the short TaV-2A sequence (19 residues) and an nsp2 that is amino-terminally extended by an additional proline residue.
The genomic DNA of the vaccinia virus recombinant vHCoV- TaV-PL1 pro (Ϫ), encoding the TaV-2A element and  an inactive PL1 pro , was used to produce full-length HCoV- TaV-PL1 pro (Ϫ) RNA. Recombinant HCoV-TaV-PL1 pro (Ϫ) could be rescued after RNA transfection into BHK-HCoV-N cells, and sequence analysis showed that both the TaV-2A element and the Cys1054Ala mutation were stably maintained in the HCoV- TaV-PL1 pro (Ϫ) genome (Fig. 5B) . Even after 10 passages in tissue culture, the TaV-2A element and the Cys1054Ala mutation were maintained, and no extra mutations were detected by sequence analysis of approximately 1 kb around the TaV-2A element and the entire PL1 pro domain in the mutant progeny. The mutant virus displayed slightly delayed growth kinetics with titers that almost reached wild-type levels at 24 h postinfection (Fig. 5C ) and were about 1 order of magnitude higher than those observed in HCoV-PL1 pro (Ϫ)- TaV-PL1 pro (Ϫ), respectively, at an MOI of 1. Virus titers are given as 50% tissue culture infective dosed (TCID 50 ) per ml of tissue culture supernatant at the indicated time points. The data points represent the means of two independent experiments. Ac, acidic domain; PL1, papain-like protease 1; X, ADPribose-1Љ-phosphatase; PL2, papain-like protease 2; Y, domain with conserved Cys/His residues and putative transmembrane regions.
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infected cells. The data demonstrate that provision of efficient nsp1-nsp2 cleavage by an alternative mechanism lifts the selection pressure on the PL1 pro (Ϫ) mutant to revert to the wild-type sequence.
DISCUSSION
In this study, we used a reverse-genetics approach to dissect the involvement of PL pro enzymes in the control of the polyprotein processing and replication of HCoV-229E, a prototypic group 1 CoV. There are a number of conclusions that can be drawn from our data. First, the proteolytic activity of PL1
pro , but not that of PL2 pro , appears to be dispensable for HCoV-229E replication. Second, there is, nevertheless, a strong selection pressure to maintain the proteolytic activity of PL1 pro , since recombinant HCoV-229E mutants lacking this activity reverted to the wild-type sequence within a few passages in tissue culture. Third, the proteolytic activity of PL1 pro is mainly required to efficiently process the nsp1-nsp2 cleavage site. Accordingly, if nsp1-nsp2 processing was functionally uncoupled from viral PL pro activities, the PL1 pro (Ϫ) genotype could be stably maintained. Finally, we were able to demonstrate that PL2 pro is capable of processing the nsp1-nsp2 site, although this reaction proceeded less efficiently than that catalyzed by PL1 pro . Our view of the PL pro -mediated pp1a/pp1ab processing pathways in HCoV-229E as derived from previously published work (28, 29, 60, 67) and this study is summarized in Fig. 6 . Among the CoVs characterized to date (7, 8, 14, 15, 27-29, 34, 36, 37, 60, 67) (Fig. 1) , HCoV-229E seems to be unique in that the proteolytic release of nsp2 appears to be mediated at both its amino-terminal and carboxy-terminal processing sites by either of the two paralogous PL pro domains (the dispensable PL1 pro or the essential PL2 pro ). Remarkably, a functional dominance of one protease over the other was evident in both these reactions, with PL1
pro being dominant at the nsp1-nsp2 site and PL2
pro being dominant at the nsp2-nsp3 site. We originally discovered this phenomenon in a study in which we investigated the processing of the HCoV-229E nsp2-nsp3 site by expressing truncated proteins from the HCoV-229E nsp2-nsp3 region in reticulocyte lysates (67) . The present study confirms the previous results and extends the data to include another cleavage site in a system that allows expression of the entire nsp1-to-nsp4 region in mammalian cells. Our data strongly suggest that the observed PL1 pro /PL2 pro redundancy at these two sites is functionally relevant for HCoV-229E replication, although it still remains technically challenging to extend these observations to the characterization of nsp1-nsp2 and nsp2-nsp3 processing in virus-infected cells. It remains to be seen whether the same redundancy applies to the processing of the nsp3-nsp4 site. The high conservation between all three cleavage sites in the HCoV-229E nsp1-to-nsp4 region (60, 67) and the predicted similarity of the substrate pockets of HCoV-229E PL1 pro and PL2 pro (54) seem to support this suggestion. If this were the case, then the essential PL2 pro could be expected to (heavily) dominate the dispensable PL1 pro in nsp3-nsp4 cleavage. As soon as suitable antibodies become available, the vaccinia virus-based HCoV-229E nsp1-to-nsp4 expression system established in this study may be used to investigate the precise mechanisms involved in the processing of the nsp3-nsp4 site.
The processing of the nsp1-to-nsp4 region appears to differ substantially between HCoV-229E and the group 2a CoV MHV, another virus with two PL pro s. A recent study of MHV PL pro processing (24) conclusively showed that, in infected cells, PL1
pro inactivation in the MHV genome results in unprocessed nsp1-nsp2 and nsp2-nsp3 sites, which have been shown by in vitro studies to be cleaved by PL1
pro . The observed processing defect in the mutant could not be compensated for by PL2
pro , possibly because, in this system, the latter enzyme is highly specialized for nsp3-nsp4 cleavage (35) . Furthermore, PL1 pro inactivation caused a severe defect in MHV RNA synthesis, and the virus reverted rapidly to the wild-type sequence if the codon specifying the active site was replaced by Ala (24) . In contrast, the equivalent HCoV-229E mutant was significantly less debilitated, and reversion occurred only after several passages in culture. Several other CoVs, e.g., SARS-CoV and IBV, employ only a single PL pro to process the aminoproximal pp1a/pp1ab region. The regulation of the proteolyticprocessing pathways in these two viruses has yet to be characterized at the same level as described above for MHV and HCoV-229E.
Comparative sequence analysis of CoVs with either one or two active PL pro s suggest that the respective nsp1 and nsp2 proteins, although being released from equivalent positions in pp1a/pp1ab, may belong to different protein families (53) (A. E. Gorbalenya, unpublished observations). Also, the proteolytic release of homologous proteins may be controlled by different types of PL pro activities in related CoVs, as exemplified by the proteolytic release of nsp1 in MHV versus SARSCoV (4, 27). In total, four different functional patterns involv- FIG. 6 . PL pro -mediated polyprotein processing in HCoV-229E. Shown are the PL pro -mediated cleavages within the amino-terminal regions of the HCoV-229E polyproteins pp1a/pp1ab. Note that cleavages of the nsp1-nsp2 and nsp2-nsp3 sites can be mediated by either PL1 pro or PL2 pro , albeit with different efficiencies. The boldface lines indicate the dominant PL pro activity at a given site, whereas thin lines indicate less efficient cleavages. The P1 and P1Ј residues of the nsp1-nsp2 and nsp2-nsp3 cleavage sites have been determined experimentally under conditions where (i) nsp1-nsp2 cleavage was mediated by PL1 pro (28) and (ii) nsp2-nsp3 cleavage was mediated by either PL1 pro or PL2 pro (67) . The predicted PL2 pro cleavage at the nsp3-nsp4 site is indicated by dotted lines. The predicted activity of PL2 pro and a potentially existing (but minor) activity of PL1 pro at the nsp3-nsp4 site remains to be studied. Ac, acidic domain; PL1, papain-like protease 1; X, ADP-ribose-1Љ-phosphatase; PL2, papain-like protease 2; Y, domain with conserved Cys/His residues and putative transmembrane regions. pro (SARS-CoV), and (iv) a group 1-specific nsp1 released by PL1 pro and possibly assisted by PL2 pro (HCoV-229E). These four patterns represent the four major phylogenetic lineages of CoVs (23) , indicating that they are separated by relatively large evolutionary distances and thus are likely to have emerged early in CoV evolution. Accordingly, when purified PL2 pro from the group 2b CoV SARSCoV was tested on cognate and heterologous peptide substrates mimicking the respective nsp3-nsp4 cleavage sites, the processing efficiency correlated with the evolutionary distance between SARS-CoV and the respective virus from which a given substrate had been derived rather than the number of proteases encoded by the virus or any other parameter (26) . Taken together, these studies suggest that the proteolytic-processing pathways of each of these CoV lineages need to be studied in more detail before a coherent model of the functional implications of differentially regulated expression strategies in this part of the CoV genome can be inferred.
Whereas PL2 pro is absolutely conserved among CoVs, PL1 pro is not. This observation has led to the hypothesis that CoVs initially evolved PL2 pro and later acquired PL1 pro through gene duplication (67) . Since CoVs encoding one or two active PL pro s phylogenetically intertwine, the repeated gain or loss, respectively, of PL1 pro during CoV evolution is a quite likely scenario. For example, it is possible that PL1 pro originated in the ancestor of the genus Coronavirus but was subsequently lost in a few branches, e.g., in groups 2b and 3. Alternatively, PL1
pro might have been introduced through independent duplications in the various branches at a later stage (67) . Irrespective of which one of these scenarios is correct, each gain/loss of PL1 pro must have been driven by a change in the selection pressure imposed by the host(s). By unraveling a link between the efficiency of nsp1-nsp2 cleavage and the need for PL1 pro activity in HCoV-229E replication, we gained, for the first time, insight into possible selection forces that might have driven the evolution of CoV PL pro activities. Our data led us to speculate that CoVs evolved a second (PL1 pro ) activity in order to diversify and thereby elaborate the proteolytic control of gene expression of the amino-proximal pp1a/pp1ab region. In group 2a CoVs (prototype, MHV), the PL1 pro and PL2 pro domains and PL pro cleavage sites diverged to an extent that allowed PL1
pro to take exclusive control of nsp1 and nsp2 production (24) . By contrast, in HCoV-229E and probably other group 1 CoVs, similar or even overlapping substrate specificities have been retained, providing these viruses with some sort of "backup" mechanism to ensure the efficient release of their amino-terminal pp1a/pp1ab proteins. Besides the use of two protease activities with overlapping specificities, other factors may be employed to ensure differential processing kinetics of specific sites in HCoV-229E. Thus, for example, both the cleavage site sequences themselves and the spatial positions of these sites in the polyprotein in relation to the enzymes' active sites are likely to be involved in the control of the efficiency of substrate binding and cleavage. Most probably, such factors are also responsible for the observed kinetic differences in PL pro -mediated polyprotein processing in SARSCoV (27) .
The observed reduction in the growth kinetics of HCoV-PL1 pro (Ϫ) and HCoV-TaV-PL1 pro (Ϫ) may indicate impaired functions of nsp1 to nsp4 (or their processing intermediates), resulting, for example, from an altered processing kinetics of the nsp1-nsp2 site. Similar defects have been reported for nsp1-nsp2 cleavage site mutants of MHV (14) and transmissible gastroenteritis virus (20) . Alternatively, the extension of nsp1 and nsp2 with short TaV-2A sequences may have compromised the structures and/or functions of the respective proteins, thereby causing the observed defects in HCoV-229E replication. Although nsp1 to nsp4 colocalize with the replicase complex at perinuclear membranes within the host cell cytoplasm, a possible involvement in viral RNA synthesis has been demonstrated only for the hydrophobic, membrane-bound nsp4 (48) . It is noteworthy that a carboxy-terminal truncation of nsp1 in MHV (11) and a complete deletion of nsp2 in MHV and SARS-CoV (25) were reported to be tolerated, indicating that nsp2 and parts of nsp1 are not essential for viral RNA synthesis. Moreover, an ADRPase-deficient HCoV-229E mutant was shown to replicate to nearly wild-type titers in tissue culture (43) . The available information on nsp1 to nsp3, including the recently described involvement of SARS-CoV nsp1 in host cell mRNA degradation (33) , the reported SARS-CoV PL pro deubiquitination activity (5, 38) , and sequence data on different isolates of bovine CoV (13) , supports the idea that specific nsp1-to-nsp3 domains may be involved in virus-host interactions.
In summary, the study extends our knowledge of the complex CoV polyprotein-processing pathways. It shows that the proteolytic processing of the amino-proximal HCoV-229E pp1a/pp1ab region is tightly regulated by an interplay between two paralogous proteolytic activities with overlapping specificities. The functional characterization of the processing products derived from this region will be essential for comprehending the biological relevance of this sophisticated regulation of protein expression and its profound variation among CoVs from the four major lineages.
